ES2612827T3 - Agente profiláctico y/o agente terapéutico para incontinencia urinaria de esfuerzo - Google Patents

Agente profiláctico y/o agente terapéutico para incontinencia urinaria de esfuerzo Download PDF

Info

Publication number
ES2612827T3
ES2612827T3 ES13790782.0T ES13790782T ES2612827T3 ES 2612827 T3 ES2612827 T3 ES 2612827T3 ES 13790782 T ES13790782 T ES 13790782T ES 2612827 T3 ES2612827 T3 ES 2612827T3
Authority
ES
Spain
Prior art keywords
urinary incontinence
agent
stress urinary
therapeutic agent
prophylactic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13790782.0T
Other languages
English (en)
Inventor
Masato Nanri
Fukumitsu SAKAKIBARA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2612827T3 publication Critical patent/ES2612827T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C07D211/50—Aroyl radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Difenilpropoxiacetato de 4-piperidilo representado por Fórmula (1),**Fórmula** o una sal del mismo para uso en la prevención o tratamiento de incontinencia urinaria de esfuerzo.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
abrió cortando mediante incisión mediana. La vejiga se expuso y se abrió cortando la parte superior de la vejiga, y después se colocó un catéter permanente para medir la presión intravesical. Después de la operación para colocar el catéter permanente, se aplicó manualmente con fuerza la presión abdominal desde el exterior. La presión intravesical cuando sucedió la pérdida urinaria se monitorizó y se usó como la PPP. Se administraron solución salina fisiológica, el
5 compuesto de la presente invención (3 mg/kg), y propiverina (3 mg/kg) como un agente terapéutico de control por vía intravenosa en una cantidad de 1 ml/kg. Cinco minutos después de la administración, se midió la PPP y se calcularon el valor medio y el error estándar. La Fig. 1 muestra los resultados.
[0046]
La PPP fue significativamente mayor en el grupo administrado el compuesto de la presente invención, en comparación
10 con el grupo de solución salina fisiológica. En contraste, no hubo diferencias significativas entre el grupo de propiverina y el grupo de solución salina fisiológica. Por tanto se reveló que el compuesto de la presente invención tiene un excelente efecto terapéutico para incontinencia urinaria de esfuerzo, y este efecto es superior al de propiverina.
Aplicabilidad Industrial
15 [0047]
El compuesto representado por Fórmula (1) o una sal del mismo de la presente invención es útil como un agente profiláctico y/o un agente terapéutico para incontinencia urinaria de esfuerzo.
7

Claims (1)

  1. imagen1
ES13790782.0T 2012-05-15 2013-05-14 Agente profiláctico y/o agente terapéutico para incontinencia urinaria de esfuerzo Active ES2612827T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012111843 2012-05-15
JP2012111843 2012-05-15
PCT/JP2013/063409 WO2013172339A1 (ja) 2012-05-15 2013-05-14 腹圧性尿失禁予防剤及び／又は治療剤

Publications (1)

Publication Number Publication Date
ES2612827T3 true ES2612827T3 (es) 2017-05-18

Family

ID=49583744

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13790782.0T Active ES2612827T3 (es) 2012-05-15 2013-05-14 Agente profiláctico y/o agente terapéutico para incontinencia urinaria de esfuerzo

Country Status (9)

Country Link
US (1) US9603845B2 (es)
EP (1) EP2851073B1 (es)
JP (1) JP5908072B2 (es)
CN (1) CN104302293B (es)
ES (1) ES2612827T3 (es)
HK (1) HK1203159A1 (es)
PL (1) PL2851073T3 (es)
TW (1) TWI544925B (es)
WO (1) WO2013172339A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004033693A1 (en) 2002-03-29 2004-04-22 Xoma Technology Ltd. Methods vectors plasmids and methods for increasing expression of recombinant polypeptides
WO2020101586A1 (en) 2018-11-16 2020-05-22 Santa Farma İlaç Sanayi̇ A.Ş. Controlled release propiverine formulations
EP4251154A1 (en) 2020-11-27 2023-10-04 Santa Farma Ilac Sanayii A.S. Sustained release formulation compositions comprising propiverine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD139212A1 (de) 1978-10-09 1979-12-19 Christian Starke Verfahren zur herstellung eines neuen arzneimittels aus alpha,alpha-diphenyl-alpha-alkoxyessigsaeure-1-methylpiperidyl-4-ester-derivaten
JPH0611758B2 (ja) * 1985-08-14 1994-02-16 大鵬薬品工業株式会社 ベンジル酸−４−ピペリジルエステル誘導体

Also Published As

Publication number Publication date
PL2851073T3 (pl) 2017-06-30
HK1203159A1 (en) 2015-10-23
EP2851073A4 (en) 2015-10-28
US20150051250A1 (en) 2015-02-19
US9603845B2 (en) 2017-03-28
CN104302293A (zh) 2015-01-21
WO2013172339A1 (ja) 2013-11-21
TWI544925B (zh) 2016-08-11
EP2851073B1 (en) 2016-11-09
EP2851073A1 (en) 2015-03-25
CN104302293B (zh) 2017-03-15
TW201350118A (zh) 2013-12-16
JPWO2013172339A1 (ja) 2016-01-12
JP5908072B2 (ja) 2016-04-26

Similar Documents

Publication Publication Date Title
SG10201804746WA (en) Surgical methods employing purified amphiphilic peptide compositions
BR112015014658A2 (pt) dispositivo para liberação de medicamento
NZ704266A (en) Inhibitors of alpha-crystallin aggregation for the treatment for cataract
ES2612827T3 (es) Agente profiláctico y/o agente terapéutico para incontinencia urinaria de esfuerzo
WO2015095811A8 (en) Combination therapy with neoantigen vaccine
MX2016009379A (es) Adaptador de cateter con compuerta con retencion de accionador de septo integrado.
WO2010014690A3 (en) Medical devices for therapeutic agent delivery
WO2007047060A3 (en) Valve for intravenous catheter
WO2015084698A3 (en) Administration and monitoring of nitric oxide in ex vivo fluids
AR083388A1 (es) Mecanismo de establecimiento de dosis
NZ721500A (en) Use of halogen compounds for the treatment and prevention of heart attack and ischemic injury
EA201491713A1 (ru) Обеспечивающий инъекции порт сосудистого доступа с различимыми метками для идентификации
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
CY1122899T1 (el) Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη
BR112017025768A2 (pt) administração intravenosa de citrulina durante cirurgia
UA100883C2 (ru) Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона
MX2022003892A (es) Soluciones intracamerales antiinflamatorias y midriaticas para inhibicion de condiciones inflamatorias oculares postoperatorias.
JP2013523739A5 (es)
CA2882211C (en) System and method of priming a surgical cassette
WO2013130891A8 (en) Intravascular line and port cleaning methods, methods of administering an agent intravascularly, methods of obtaining/testing blood, and devices for performing such methods
ECSP10010381A (es) Asociacion entre una sal de bis-tiazolio o uno de sus precursores y artemisinina o uno de sus derivados para el tratamiento del paludismo grave
RU2014106575A (ru) Способ профилактики кровотечения при миомэктомии
WO2006063091A3 (en) Use of oxypurinol as an inhibitor of anti-neoplastic agent-induced cardiotoxicity
WO2015017218A3 (en) Titration for medical infusion devices and systems